Which Companies Will Be Making the News in 2024?

Which companies will be making the news this year—from manufacturing expansions, to mergers & acquisitions, to other key strategic developments? Be among the newsmakers at The DCAT Member Company Announcement Forum at DCAT Week. Applications close Monday February 5.

Which companies will be making the news this year—from manufacturing expansions, to mergers & acquisitions, to other key strategic developments? Be among the newsmakers at The DCAT Member Company Announcement Forum at DCAT Week. Applications close Monday February 5.

Getting the latest news at DCAT Week
Kicking off DCAT Week, the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT) and the premier industry event for companies engaged in bio/pharmaceutical development and manufacturing, the DCAT Member Company Announcement Forum is a much-anticipated program in which senior executives from DCAT Member Companies highlight major news from their companies most impactful to the global bio/pharmaceutical manufacturing value chain.

The program is where the industry gathers to hear about the latest manufacturing expansions across all segments: chemicals/chemical active pharmaceutical ingredient (API) manufacturing, biomanufacturing, drug-product manufacturing, and packaging. It is an opportunity to get the details on the capacity being added, when it is coming on line, and the levels of investment behind those expansions.

It is also where the industry comes to get an inside take on the latest in mergers and acquisitions (M&A) from the deal-makers themselves. Senior executives explain their companies’ strategic rationale behind their moves to build critical mass and the details behind those moves: updates on deal closure and post-M&A integration.  

The program is open to all DCAT Member Companies—bio/pharma companies, CDMOs/CMOs, and other suppliers—but companies must apply to be considered for a presentation slot for this prominent event and much sought-after podium time. 

Applications are closing Monday February 5, 2024. The DCAT Member Company Announcement Forum Oversight Committee will then select companies given podium time based on news priority and interest to DCAT Member Companies. A company’s news must be from 2024 and can involve a merger or acquisition, manufacturing expansion, or other major corporate strategic development. Content criteria and online applications can be found here.

Due to popular demand and the number of applications received, this year’s Forum has been expanded and will be held from 9:00 to 11:30 AM on Monday March 18, 2024. Companies of all sizes—large-, medium-, and small-sized companies—may apply to highlight announcements of importance to the industry. But presentation slots are limited, and applications must be received no later than Monday February 5, 2024.

Need examples of past announcements? Check out the companies that made the news at DCAT Week 2023.

Expect a full house and standing room only of DCAT Week’s influential attendees of senior to mid-level executives to be at the program. The DCAT Member Company Announcement Forum will be held at DCAT Week on Monday, March 18, 2024, from 9:00 to 11:30 AM, at the InterContinental Barclay, Grand Ballroom, in New York. Interested in attending? Click here for further information, including how to register to attend.    

Recent Feature Articles

Radiopharmaceuticals: A Niche But Growing Sector

By
Although a niche area, market interest in radiopharmaceuticals is on the rise as certain bio/pharma majors and smaller companies strike drug-development deals and CDMOs/CMOs specializing in this area expand production capacity. 

The EU’s Rare-Disease Moonshot & Orphan Drug Market

By
This week marks the second anniversary of the launch of the EU’s “Rare Disease Moonshot,” a commitment by nine European associations to break down barriers to advance development of therapeutics…

Bio/Pharma’s Rising Stars: The Companies Emerging on the Industry’s Radar

By
Which bio/pharma companies and CEOs may be under the industry’s radar but are executing better-than expected performance and winning strategies for their companies? What products—development and commercial—are delivering? DCAT Value Chain Insights takes an inside look.

A Shortage of Inspectors Curtailing FDA Inspections: The Impact on Pharma

By
FDA conducted 621 foreign and 444 domestic inspections in fiscal year 2023, which was up from pandemic levels when in-person inspections were paused, but 36% fewer than pre-pandemic levels. A shortage of inspectors is a major factor. What’s the impact on Pharma?